Advanced biologics technology platform for next-gen immunotherapies
Unlocking the power of T cells against oncogenic driver mutations
Discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers
Allogeneic CAR T (AlloCAR T ™) therapies for cancer (NASDAQ: ALLO)
Developing alteration-specific targeted therapies for the treatment of cancer
Focused on discovering, developing and manufacturing next-generation, transformative TCR therapies targeting neoantigens in solid cancers
Acquired by Bayer in 2020
Developing targeted inhalation therapies for life-threatening pulmonary diseases
Developing potentially transformative drugs to address autoimmune diseases
Developing therapeutics to reprogram immune cells for a broad range of diseases
A novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs (NASDAQ: CNTA)
Developing life-transforming therapies for patients with serious muscle diseases (NASDAQ: DYN)
Developing a novel class of cancer therapies called RIPTACTM (Regulated Induced Proximity Targeting Chimeras) therapeutics
Pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer
Developing novel therapeutics based on identification and manipulation of protein pairings
Pursuing therapies against some of the most intractable cancer targets (NASDAQ: KRON)
Developing cell therapies to treat autoimmune diseases (NASDAQ: KYTX)
Developing innovative therapies for neuropsychiatric diseases, including schizophrenia
Personalized T cell therapies to treat cancer
Acquired by AstraZeneca in 2023
Advancing first-in-class small molecule therapies
Acquired by Merck in 2019
Supporting biopharmaceutical clients through clinical development and commercialization
Dedicated to finding novel solutions for protein misfolding diseases
Pioneering complex-directed therapies to treat RAS-driven cancer types
Targeting the underlying genetic cause of disease for underserved patients
Target Engaged: Broadening the reach and impact of precision medicine for oncology
Transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies
Developing multifunctional antibodies that are optimized for best-in-class T cell engagement across solid tumors and inflammatory & immunology (I&I) disease
Harnessing the power of microglia for the treatment of neurodegenerative diseases (NASDAQ: VIGL)
Developing novel therapies for the prevention and treatment of metastatic cancer
